TVRD
NASDAQTvardi Therapeutics Inc.
Tvardi Therapeutics Inc. (TVRD) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 2 wire items for TVRD, including 1 press release or news item and 1 analyst rating. The most recent was published Oct 20, 2026.
Financial highlights
Full financials- Net income, TTM
- -$26.06M
- Cash
- $15.77M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks20+100%
2026-05-102026-11-01
Mix890d
- Other5(63%)
- SEC Filings2(25%)
- Analyst1(13%)
Latest news
25 items- ANALYSTChardan Capital Markets initiated coverage on Tvardi Therapeutics with a new price targetChardan Capital Markets initiated coverage of Tvardi Therapeutics with a rating of Buy and set a new price target of $8.00
- PRTvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare ConferenceHOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will present at Chardan’s 10th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026, at 1:30 PM ET. Members of the Tvardi management team will be available to meet with investors who are registered to attend the conference. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small mo
- PRNew Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated STAT3-driven disease biology Collective findings now span multiple preclinical models of UC, further supporting the scientific rationale for advancing TTI-109, Tvardi’s next-generation STAT3 inhibitor, in UC HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative
- PRTvardi Therapeutics to Participate in Upcoming Investor EventsHOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events: Wells Fargo 21st Annual Healthcare ConferenceFormat: 1-on-1 MeetingsDate: Wednesday, September 9, 2026Location: Boston, MA 2026 Cantor Global Healthcare ConferenceFormat: Fireside Chat and 1-on-1 MeetingsDate: Thursday, September 10, 2026Time: 10:55 AM ETLocation: New York, NY H.C. Wainwright 28th Annual Global Investment Confere
- SECSEC Form 10-Q filed by Tvardi Therapeutics Inc.10-Q - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- SECTvardi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- PRTvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business UpdateReported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations Announced ulcerative colitis (UC) as the initial disease indication for TTI-109 and will host a KOL webinar on the clinical potential of TTI-109 in UC on August 19, 2026, at 11:00 a.m. ET HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its
- PRTvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026HOUSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that it will host a KOL webinar on Wednesday, August 19, 2026 at 11:00 AM ET featuring Randy Longman, MD, PhD (Weill Cornell Medicine), who will join Tvardi management to discuss the current treatment landscape in ulcerative colitis (UC) and the persistent unmet needs that remain despite recent clinical advances and currently approved therapies. The event will feature new data from Tvardi
- SECTvardi Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- PRTvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday, August 19 at 11:00
- SECTvardi Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- SECSEC Form 424B5 filed by Tvardi Therapeutics Inc.424B5 - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- ANALYSTTvardi Therapeutics upgraded by Piper Sandler with a new price targetPiper Sandler upgraded Tvardi Therapeutics from Neutral to Overweight and set a new price target of $13.00
- ANALYSTTvardi Therapeutics upgraded by Raymond James with a new price targetRaymond James upgraded Tvardi Therapeutics from Mkt Perform to Outperform and set a new price target of $10.00
- SECTvardi Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- PRTvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target EngagementTTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) and B cells Company plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal (GI) diseases - subject to additional funding Company to host investor webcast today, July 7th, at 8:30am ET HOUSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, t
- ANALYSTH.C. Wainwright initiated coverage on Tvardi Therapeutics with a new price targetH.C. Wainwright initiated coverage of Tvardi Therapeutics with a rating of Buy and set a new price target of $9.00
- PRTvardi Therapeutics to Participate in Upcoming Investor EventsHOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events: Jefferies Global Healthcare ConferenceFormat: Fireside Chat and 1-on-1 MeetingsDate: Thursday, June 4, 2026Time: 8:10 AM ETLocation: New York, NY Raymond James BioPharma CEO Strategy SeriesFormat: Fireside ChatDate: Friday, June 5, 2026Time: 10:00 AM ETRegistration Link: Here The webcasts of the Jefferies and Raymond James firesid
- SECSEC Form EFFECT filed by Tvardi Therapeutics Inc.EFFECT - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- SECSEC Form EFFECT filed by Tvardi Therapeutics Inc.EFFECT - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- SECSEC Form POS AM filed by Tvardi Therapeutics Inc.POS AM - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- SECSEC Form 10-Q filed by Tvardi Therapeutics Inc.10-Q - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- SECTvardi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
- PRTvardi Therapeutics Announces First Quarter 2026 Results and Provides Business UpdateTopline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) on track for 2H 2026 Cash runway expected to be sufficient to fund operations through clinical readouts and into Q4 2026 HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the first quarter ended Mar
- SECSEC Form S-3 filed by Tvardi Therapeutics Inc.S-3 - Tvardi Therapeutics, Inc. (0001346830) (Filer)
TVRD FAQ
9 questionsWhat is the latest news on TVRD?
In the last 30 days Quantisnow tracked 2 wire items for TVRD: 1 press release or news item and 1 analyst rating. The most recent was published on October 20, 2026.Is TVRD profitable?
No. Tvardi Therapeutics Inc. reported a net loss of $26.06M for the twelve months ended Jun 30, 2026.How much cash and debt does TVRD have?
Tvardi Therapeutics Inc. reported $15.77M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does TVRD stock trade?
Tvardi Therapeutics Inc. (TVRD) is listed on NASDAQ.What sector and industry is TVRD in?
Tvardi Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Tvardi Therapeutics Inc. go public?
Tvardi Therapeutics Inc. (TVRD) completed its IPO in 2014.What are analysts saying about TVRD?
Across the last 8 analyst actions on Tvardi Therapeutics Inc., there were 2 upgrades and 4 downgrades. The most recent action was from Chardan Capital Markets: Buy with a $8.00 price target on 2026-10-20. Recent price targets range from $3.00 to $13.00.What companies are similar to TVRD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TVRD side-by-side with any of them on Quantisnow.How can I track TVRD on Quantisnow?
Quantisnow aggregates Tvardi Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TVRD to receive live email and push alerts on every new disclosure.